News Introducing Robin Markowitz, CEO Lymphoma Canada is pleased to announce the appointment of our new CEO, Robin Markowitz. She…adminDecember 11, 2013
News Survivor Tips For many, the word “survivor” summons up images of strong, fit, beautiful, and tanned participants…adminDecember 9, 2013
News Lymphoma: A Wake-up Call For Anthony Liscio, a diagnosis of stage III Hodgkin lymphoma nine years ago was “a…adminDecember 9, 2013
News Celebrating a Friend A year ago, if you saw Kristen Christie running, “there was either someone chasing me…adminDecember 9, 2013
News Bend All Automotive supports Lymphoma Canada A heartfelt vote of thanks to Bend All Automotive in Ayr, Ontario and to the…adminDecember 9, 2013
Press Releases Lymphoma Canada Appoints Robin Markowitz CEO Lymphoma Canada is pleased to announce the appointment of Robin Markowitz as Chief Executive Officer,…adminNovember 21, 2013
Research Y-ibritumomab tiuxetan and high-dose BEAM chemotherapy conditioning followed by autologous stem cell transplantation shows encouraging response and survival rates in refractory diffuse large B-cell lymphoma patients Although combination rituximab and chemotherapy treatment has improved the survival of patients with diffuse large…adminNovember 18, 2013
Research Potential Role of Lymphocyte Development Gene Variants in Non-Hodgkin Lymphoma Risk The risk of developing NHL can be influenced by both environmental and genetic factors that…adminNovember 7, 2013
Research Rituximab helps overcome adverse effects of diabetes mellitus for patients with diffuse large B-cell lymphoma. Diabetes mellitus, also known colloquially just as diabetes, is a group of metabolic diseases in…adminNovember 7, 2013
Research LR11: a novel biomarker identified in follicular lymphoma Follicular Lymphoma, or Fl, is the second most frequent type of non-Hodgkin lymphoma, and is…adminSeptember 16, 2013